Literature DB >> 17916218

Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases.

R Rios-Fernández, M T Gutierrez-Salmerón, J-L Callejas-Rubio, M Fernández-Pugnaire, N Ortego-Centeno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17916218     DOI： 10.1111/j.1365-2133.2007.08189.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  12 in total

Review 1.  Rituximab-associated neutropenia.

Authors:  Kieron Dunleavy; Kevin Tay; Wyndham H Wilson
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

2.  Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Eugene P Rhee; Karen A Laliberte; John L Niles
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

3.  Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.

Authors:  Wen-Kai Weng; Robert S Negrin; Philip Lavori; Sandra J Horning
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

Review 4.  Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review.

Authors:  Chang-Yu Hsieh; Tsen-Fang Tsai
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859

5.  Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment.

Authors:  Tatiana Reitblat; Alexander Wechsler; Olga Reitblat
Journal:  Am J Case Rep       Date:  2015-04-09

Review 6.  Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians.

Authors:  Muhammad Abdul Mabood Khalil; Muhammad Ashhad Ullah Khalil; Taqi F Taufeeq Khan; Jackson Tan
Journal:  J Transplant       Date:  2018-08-01

7.  A case of late-onset neutropenia secondary to rituximab in a patient with mucous membrane pemphigoid.

Authors:  Brittney Schultz; Donna Culton
Journal:  JAAD Case Rep       Date:  2019-08-05

8.  Rituximab in the treatment of pemphigus vulgaris.

Authors:  Labib R Zakka; Shawn S Shetty; A Razzaque Ahmed
Journal:  Dermatol Ther (Heidelb)       Date:  2012-11-15

9.  Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.

Authors:  Elena Schiopu; Soumya Chatterjee; Vivien Hsu; Armando Flor; Daniel Cimbora; Kaushik Patra; Wenliang Yao; Jing Li; Katie Streicher; Kathleen McKeever; Barbara White; Eliezer Katz; Jorn Drappa; Sarah Sweeny; Ronald Herbst
Journal:  Arthritis Res Ther       Date:  2016-06-07       Impact factor: 5.156

10.  Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.

Authors:  J H Salmon; P Cacoub; B Combe; J Sibilia; B Pallot-Prades; O Fain; A Cantagrel; M Dougados; E Andres; O Meyer; P Carli; E Pertuiset; I Pane; F Maurier; P Ravaud; X Mariette; J E Gottenberg
Journal:  RMD Open       Date:  2015-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.